Get it on Google Play

aTyr Pharma reaches FDA alignment on Phase 3 efzofitimod study

September 24, 2026 6:00 AM EDT Send to a Friend
aTyr Pharma, Inc. (Nasdaq: ATYR) announced it has reached alignment with the U.S. Food and Drug Administration on the protocol ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login